These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37525895)

  • 21. Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
    Ayyagari R; Tang D; Patterson-Lomba O; Zhou Z; Xie J; Chandiwana D; Dalal AA; Niravath PA
    Curr Med Res Opin; 2018 Sep; 34(9):1645-1652. PubMed ID: 29781326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal duration of prior endocrine therapy predicts the efficacy of Fulvestrant in a real-world study for patients with hormone receptor-positive and HER2-negative advanced breast cancer.
    Zhao Y; Li Y; Gong C; Xie Y; Zhang J; Wang L; Cao J; Tao Z; Wang B; Hu X
    Cancer Med; 2020 Dec; 9(23):8821-8831. PubMed ID: 33022852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.
    Blancas I; Fontanillas M; Conde V; Lao J; Martínez E; Sotelo MJ; Jaen A; Bayo JL; Carabantes F; Illarramendi JJ; Gordon MM; Cruz J; García-Palomo A; Mendiola C; Pérez-Ruiz E; Bofill JS; Baena-Cañada JM; Jáñez NM; Esquerdo G; Ruiz-Borrego M
    Clin Transl Oncol; 2018 Jul; 20(7):862-869. PubMed ID: 29178019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
    Watanabe K; Niikura N; Kikawa Y; Oba M; Kobayashi K; Tada H; Ozaki S; Toh U; Yamamoto Y; Tsuneizumi M; Okuno T; Iwakuma N; Takeshita T; Iwamoto T; Ishiguro H; Masuda N; Saji S
    Breast Cancer Res Treat; 2023 Jun; 199(2):253-263. PubMed ID: 37000345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
    Martín M; Zielinski C; Ruiz-Borrego M; Carrasco E; Ciruelos EM; Muñoz M; Bermejo B; Margelí M; Csöszi T; Antón A; Turner N; Casas MI; Morales S; Alba E; Calvo L; de la Haba-Rodríguez J; Ramos M; Murillo L; Santaballa A; Alonso-Romero JL; Sánchez-Rovira P; Corsaro M; Huang X; Thallinger C; Kahan Z; Gil-Gil M
    Eur J Cancer; 2022 Jun; 168():12-24. PubMed ID: 35429901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.
    Goldschmidt D; Dalal AA; Romdhani H; Kelkar S; Guerin A; Gauthier G; Wu EQ; Niravath P; Small T
    Adv Ther; 2018 Apr; 35(4):482-493. PubMed ID: 29582246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR
    Musolino A; Campone M; Neven P; Denduluri N; Barrios CH; Cortes J; Blackwell K; Soliman H; Kahan Z; Bonnefoi H; Squires M; Zhang Y; Deudon S; Shi MM; André F
    Breast Cancer Res; 2017 Feb; 19(1):18. PubMed ID: 28183331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
    Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
    Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.
    Ozaki Y; Aoyama Y; Masuda J; Inagaki L; Kawai S; Shibayama T; Maeda T; Kurata M; Yoshida K; Saeki S; Hosonaga M; Fukada I; Hara F; Kobayashi T; Kobayashi K; Miyake S; Takano T; Ueno T; Ohno S
    BMC Cancer; 2022 Jan; 22(1):36. PubMed ID: 34983437
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of fulvestrant 500 mg in Japanese postmenopausal advanced/recurrent breast cancer patients and factors associated with prolonged time-to-treatment failure.
    Araki K; Ishida N; Horii R; Takahashi S; Akiyama F; Ito Y; Ohno S
    Expert Opin Pharmacother; 2015; 16(17):2561-8. PubMed ID: 26558799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study.
    Taylor-Stokes G; Mitra D; Waller J; Gibson K; Milligan G; Iyer S
    Breast; 2019 Feb; 43():22-27. PubMed ID: 30391832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy.
    Heo MH; Kim HK; Lee H; Kim JY; Ahn JS; Im YH; Park YH
    Korean J Intern Med; 2019 Sep; 34(5):1100-1106. PubMed ID: 29540055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients.
    Liu J; Li J; Wang H; Wang Y; He Q; Xia X; Hu ZY; Ouyang Q
    J Transl Med; 2019 Jan; 17(1):27. PubMed ID: 30646914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs.
    Cobleigh M; Yardley DA; Brufsky AM; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Hurvitz SA; O'Shaughnessy J; Mason G; Antao V; Li H; Chu L; Jahanzeb M
    Clin Cancer Res; 2020 Mar; 26(5):1105-1113. PubMed ID: 31772121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.
    García-Sáenz JÁ; Martínez-Jáñez N; Cubedo R; Jerez Y; Lahuerta A; González-Santiago S; Ferrer N; Ramos M; Alonso-Romero JL; Antón A; Carrasco E; Chen J; Neuwirth R; Galinsky K; Vincent S; Leonard EJ; Slamon D
    Clin Cancer Res; 2022 Mar; 28(6):1107-1116. PubMed ID: 34980598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Palbociclib combined with endocrine therapy in heavily pretreated HR
    Manso L; Hernando C; Galán M; Oliveira M; Cabrera MA; Bratos R; Rodríguez CA; Ruiz-Borrego M; Blanch S; Llombart-Cussac A; Delgado-Mingorance JI; Álvarez-Busto I; Gallegos I; González-Cortijo L; Morales S; Aguirre E; Hernando BA; Ballesteros A; Alés-Martínez JE; Reboredo C; Oltra A; González-Cao M; Santisteban M; Malón D; Echeverría I; García-Garre E; Vega E; Servitja S; Andrés R; Robles CE; López R; Galve E; Echarri MJ; Legeren M; Moreno F
    Breast; 2020 Dec; 54():286-292. PubMed ID: 33242755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
    Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
    Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China.
    Lei W; Li H; Song G; Zhang R; Ran R; Yan Y; Di L; Jiang H
    J Cancer; 2020; 11(22):6612-6622. PubMed ID: 33046982
    [No Abstract]   [Full Text] [Related]  

  • 39. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE.
    Johnston SRD; Hegg R; Im SA; Park IH; Burdaeva O; Kurteva G; Press MF; Tjulandin S; Iwata H; Simon SD; Kenny S; Sarp S; Izquierdo MA; Williams LS; Gradishar WJ
    J Clin Oncol; 2021 Jan; 39(1):79-89. PubMed ID: 32822287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter Observational Study of Fulvestrant 500 mg in Postmenopausal Japanese Women with Estrogen Receptor-Positive Advanced or Recurrent Breast Cancer after Prior Endocrine Treatment (SBCCSG29 Study).
    Kimizuka K; Inoue K; E Nagai S; Saito T; Nakano S; Futsuhara K; Yamada H; Kaneko S; Sakurai T; Hata S; Kurosumi M
    J Nippon Med Sch; 2019; 86(3):165-171. PubMed ID: 31292328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.